Molecular imaging is progressing into the clinic, but as in the research world, a host of thorny questions has yet to be resolved before opportunities can be optimized. By Wendy Diller In February of
The stock-market hype is over—but the research and start-up activity is hotter than ever. It may have been the single greatest instance of bio-stock hype since the IPO of Genentech Inc. two decades